News >

ASCO Names Progress in Treating Rare Cancers as Advance of the Year

Kristi Rosa
Published: Thursday, Jan 31, 2019

Monica M. Bertagnolli, MD, FACS, FASCO

Monica M. Bertagnolli, MD, FACS, FASCO

Due to major advancements made within the past year in the development of new therapies for patients with difficult-to-treat, rare cancers, ASCO has selected progress in treating rare cancers as its Advance of the Year.1

ASCO made the announcement as part of Clinical Cancer Advances 2019: ASCO’s Annual Report on Progress Against Cancer. The annual update on oncology treatment highlights the most impactful clinical research milestones and policy developments that have been achieved over the past year.

ASCO President Monica M. Bertagnolli, MD, FACS, FASCO, said in a press release that when it comes to furthering the progress made in the cancer space as a whole, especially in rare cancers where there is a great deal of unmet need, federal investment is critical.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication